Secretory leukoprotease inhibitor: partnering alpha 1-proteinase inhibitor to combat pulmonary inflammation.
Secretory leukoprotease inhibitor (SLPI) is a low molecular weight serine proteinase inhibitor, notably of neutrophil elastase (NE), which is synthesised and secreted by the pulmonary epithelium. SLPI plays an important role in limiting NE-induced pulmonary inflammation and, significantly, it also possesses anti-HIV activity. SLPI is a significant component of the anti-NE shield in the lung which has different reactivity from, and is therefore complementary to, the anti-NE action of alpha 1-proteinase inhibitor (alpha 1-PI). Inhaled recombinant SLPI (rSLPI) could prove beneficial in partnership with alpha 1-PI in the treatment of a number of inflammatory lung disorders including emphysema, chronic bronchitis, cystic fibrosis, and adult respiratory distress syndrome.
Bingle
L
L
Department of Medicine, Charing Cross and Westminster Medical School, London, UK.
Tetley
T D
TD
D000818:Animals; D004359:Drug Therapy, Combination; D007249:Inflammation / Q000188:drug therapy; D019272:Leukocyte Elastase / Q000037:antagonists & inhibitors; D008171:Lung Diseases / Q000188:drug therapy*; D053491:Proteinase Inhibitory Proteins, Secretory; D011506:Proteins / Q000502:physiology / Q000627:therapeutic use*; D012756:Sheep; D000515:alpha 1-Antitrypsin / Q000502:physiology / Q000627:therapeutic use*
D053491:Proteinase Inhibitory Proteins, Secretory; D011506:Proteins; D000515:alpha 1-Antitrypsin; D019272:Leukocyte Elastase